DRG Fingertip insights
보험 플랜, 정책 제한, PBM, 의료 제공자 등 마켓 액세스 의사결정에 필요한 데이터와 인사이트를 제공합니다.
Formulary Advantages in Type 2 Diabetes: Impact of Current and Future DPP-IV Inhibitors and GLP-1 Analogues on Advantaged Reimbursement Status for Key Brands
Type 2 diabetes currently affects almost 24 million in the United States and the prevalence of the disease is set to grow at approximately 3% per year over the next five years. As biopharmaceutical co…